Brooks Laboratories Ltd
Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment[1]
- Market Cap ₹ 225 Cr.
- Current Price ₹ 85.7
- High / Low ₹ 186 / 72.5
- Stock P/E
- Book Value ₹ 25.0
- Dividend Yield 0.00 %
- ROCE -24.7 %
- ROE -28.1 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 3.43 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -21.3% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
77 | 91 | 63 | 79 | |
77 | 105 | 90 | 97 | |
Operating Profit | 1 | -14 | -26 | -18 |
OPM % | 1% | -16% | -42% | -23% |
1 | 1 | -3 | 1 | |
Interest | 3 | 3 | 2 | 1 |
Depreciation | 7 | 7 | 7 | 2 |
Profit before tax | -9 | -24 | -38 | -20 |
Tax % | -115% | 19% | 19% | -0% |
-19 | -19 | -31 | -20 | |
EPS in Rs | -7.40 | -4.31 | -7.98 | -7.46 |
Dividend Payout % | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 1% |
TTM: | 26% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 0% |
TTM: | -4% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 19% |
3 Years: | -1% |
1 Year: | 14% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -21% |
Last Year: | -28% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Equity Capital | 25 | 25 | 25 | 26 |
Reserves | 54 | 63 | 49 | 39 |
31 | 25 | 7 | 6 | |
52 | 83 | 29 | 19 | |
Total Liabilities | 162 | 196 | 110 | 90 |
108 | 110 | 15 | 14 | |
CWIP | 1 | 15 | 0 | 0 |
Investments | 0 | 0 | 64 | 43 |
54 | 71 | 31 | 34 | |
Total Assets | 162 | 196 | 110 | 90 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
4 | -37 | -14 | -10 | |
-5 | -25 | 0 | 0 | |
1 | 64 | 11 | 10 | |
Net Cash Flow | 0 | 2 | -3 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|
Debtor Days | 65 | 71 | 74 | 75 |
Inventory Days | 178 | 157 | 80 | 62 |
Days Payable | 233 | 159 | 165 | 100 |
Cash Conversion Cycle | 9 | 68 | -12 | 37 |
Working Capital Days | -5 | 95 | -3 | 58 |
ROCE % | -16% | -28% |
Documents
Announcements
- Closure of Trading Window 26 Jun
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Secretarial Compliance Report for the Financial Year ended 31st March, 2024
- Announcement under Regulation 30 (LODR)-Newspaper Publication 19 May
- Financial Results For Quarter And Financial Year Ended March 31, 2024 18 May
- Board Meeting Outcome for Board Meeting Outcome For Submission Of Audited Standalone And Consolidated Financial Results For Quarter And Financial Year Ended March 31, 2024. 18 May
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
BLL is an EU GMP & ISO 9001:2008 certified manufacturer and marketer of pharmaceutical formulations